Benzodiazepine receptor ligands: a patent review (2006 – 2012)
نویسندگان
چکیده
منابع مشابه
Optimum Conditions of Radioligand Receptor Binding Assay of Ligands of Benzodiazepine Receptors
To obtain drugs which are more selective at benzodiazepine (BZD) receptors, design and synthesis of functionally selective ligands for BZD receptors is the current strategy of our pharmaceutical chemistry department. The affinity of newly synthesized ligands is assessed by radioligand receptor binding assays. Based on our previous studies, 2-phenyl-5-oxo-7-methyl-1,3,4-oxadiazolo[a,2,3]-pyrimid...
متن کاملOptimum Conditions of Radioligand Receptor Binding Assay of Ligands of Benzodiazepine Receptors
To obtain drugs which are more selective at benzodiazepine (BZD) receptors, design and synthesis of functionally selective ligands for BZD receptors is the current strategy of our pharmaceutical chemistry department. The affinity of newly synthesized ligands is assessed by radioligand receptor binding assays. Based on our previous studies, 2-phenyl-5-oxo-7-methyl-1,3,4-oxadiazolo[a,2,3]-pyrimid...
متن کاملImaging of a glioma using peripheral benzodiazepine receptor ligands.
Two types of benzodiazepine receptors have been demonstrated in mammalian tissues, one which is localized on neuronal elements in brain and the other, on glial cells and in peripheral tissues such as kidney. In vivo administration of 3H-labeled PK 11195 [1-(2-chlorophenyl-N-methyl-N-(1-methylpropyl)-3-isoquinoline carboxamide] or [3H]flunitrazepam with 5 mg of clonazepam per kg to rats with int...
متن کاملLigands of the GABAA Receptor Benzodiazepine Binding Site
Benzodiazepine (BZ) binding site ligands are important central nervous system (CNS) drugs. Their numbers and our knowledge of how they interact with the BZ-binding site of GABAA receptors are both rapidly expanding. The GABAA receptor is a member of the ligand-gated ion channel superfamily. In general, it consists of an assembly of transmembrane pentamers of different subunit compositions (1). ...
متن کاملIndoleamine 2,3-dioxygenase inhibitors: a patent review (2008 - 2012).
INTRODUCTION The inhibition of indoleamine 2,3-dioxygenase (IDO) has emerged as a key area in cancer immunotherapy in the past decade. Despite the large variety of potential inhibitors screened so far, the number of active scaffolds remains limited. AREAS COVERED All relevant patent literature published between 2008 and 2012 is reviewed. Representative examples are given for each patent and/o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Expert Opinion on Therapeutic Patents
سال: 2013
ISSN: 1354-3776,1744-7674
DOI: 10.1517/13543776.2013.782005